Kraig Biocraft Laboratories, Inc. (KBLB) Form 424B3 — May 22, 2026

Kraig Biocraft Laboratories filed a prospectus supplement updating its shelf registration with its Q1 2026 financial results, which reveal severe financial distress. The company reported $0 in revenue and a net loss of $942,720 for the quarter, bringing its accumulated deficit to $57.7 million. The filing includes explicit going-concern language, stating that net losses and capital deficiency raise substantial doubt about the company's ability to continue operations. As of March 31, 2026, Kraig held only $2.9 million in cash against $10.8 million in total liabilities, resulting in a working capital deficit of $7.7 million.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.